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A wide variety of different functions and an impressive array of interactors have been
associated with leucine-rich repeat kinase 2 (LRRK2) over the years. Here, I discuss the
hypothesis that LRRK2 may be capable of interacting with different proteins at different
times and places, therefore, controlling a plethora of diverse functions based on the dif-
ferent complexes formed. Among these, I will then focus on macroautophagy in the
general context of the endolysosomal system. First, the relevance of autophagy in
Parkinson’s disease will be evaluated giving a brief overview of all the relevant
Parkinson’s disease genes; then, the association of LRRK2 with macroautophagy and
the endolysosomal pathway will be analyzed based on the supporting literature.
Introduction
Leucine-rich repeat kinase 2 (LRRK2) is the gene most frequently mutated in familial Parkinson’s
disease (PD); seven coding mutations characterized by population-speciﬁc penetrance (N1437H,
R1441G, R1441C, R1441H, Y1699C, G2019S and I2020T) are cause of dominant, late-onset PD [1],
while coding and noncoding polymorphisms in the LRRK2 locus are associated with an increased risk
of sporadic disease [2]. Interestingly, PD is not the sole disease in which LRRK2 holds genetic rele-
vance. The risk of certain types of cancer appears to be modulated by LRRK2-PD mutations [3];
moreover, noncoding polymorphisms in the LRRK2 locus are associated with an increased risk of
leprosy [4] and inﬂammatory bowel disorder [5]. Of note, though LRRK2 is an ubiquitous gene, its
expression is elevated within the immune system, and plays an important role in glia [6], suggesting
that tissue homeostasis in health and disease may be regulated by the immune system through LRRK2
activity. The protein product of the LRRK2 gene is an enzyme (∼280 kDa) containing active kinase
and GTPase catalytic sites surrounded by protein interaction domains [7–8]. Over the past 10 years,
copious efforts have been dedicated to the dissection of the LRRK2 function and to the search for
LRRK2 substrates and interactors.
LRRK2: one protein — multiple partners — multiple
functions
A wide variety of different functions have been associated with LRRK2 over the years, including
various signaling pathways, autophagy, vesicle trafﬁcking, vesicle recycling at the synapses, protein
synthesis, gene expression, mitochondria homeostasis and immune system-speciﬁc activities [9]. A
bioinformatics survey from our group revealed that 269 putative LRRK2 interactors were published in
peer-reviewed journals, and this ﬁgure was scaled down to 62 interactors when ﬁlters were applied to
control for data replication [10]. This scale and variety of putative LRRK2 interactors suggests that
LRRK2 may behave as a ‘date-hub’, term that, in systems biology, refers to a dynamic protein capable
of forming different complexes at different locations and times [11]. Under this perspective, LRRK2
may be capable of interacting with different proteins, therefore, controlling a plethora of diverse func-
tions based on the complexes formed in different tissues, cell types, stages of development or under
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speciﬁc stimuli [12]. The date-hub hypothesis is intriguing because it provides a plausible reason as to why
multiple functions and so many partners have been associated with LRRK2 over the past decade, and why the
search for the unique LRRK2 role has revealed challenging. In fact, the concept of just one singular LRRK2
function may be misleading, and the experimental design (cell type, moment in development and experimental
conditions) might play a determinant role in how the LRRK2 complex is formed, affecting the function
that LRRK2 supports and that the experiment describes. Therefore, more precision is needed in characterizing
the model system in which the study of LRRK2 is conducted. Another consequence is that among all the
possible LRRK2 functions, only few will be relevant to disease. It will therefore be necessary to deﬁne a general
group containing all LRRK2 functions among which the smaller subset of disease-associated ones can be
identiﬁed.
PD and the autophagy–endolysosomal pathway
One of the functions LRRK2 has been associated with is autophagy, in the more general scenario of the endoly-
sosomal system. This speciﬁc association is appealing because all the diseases associated with LRRK2 have
been, to different extents, related with alterations of autophagy. In the case of PD, this association echoes
results of functional studies performed with other PD genes (Figure 1) opening to the possibility that altera-
tions in the autophagy–endolysosomal pathway might be an underlying common mechanism at the base of PD
neurodegeneration.
SNCA was the ﬁrst gene being associated with PD by either mutations [13] or copy number variations [14];
α-synuclein, the protein product of the SNCA gene, misfolds and deposits as amyloid material forming Lewy
bodies, one of the pathological hallmarks of PD. The function of α-synuclein is still not known; it has been
suggested that it may exert a chaperone activity at the synapse facilitating vesicle dynamics [15]. Mutated
α-synuclein is known to impair chaperone-mediated autophagy (CMA) [16], and it is assumed that a change
in the balance between its production and degradation rates may lead to its accumulation during PD. PD
genome-wide association studies (PD-GWAS) suggested different candidate genes as risk factors for sporadic
PD [17] among which RAB7L1 and cyclin-G-associated kinase (GAK) were further proposed to interact with
LRRK2 forming a complex to promote clearance of Golgi-derived vesicles through macroautophagy [18,19].
VPS35 (vacuolar protein sorting-associated protein 35) is mutated in rare forms of familial PD; it is a com-
ponent of the retromer complex that mediates the distribution of proteins in the endosome–Golgi–lysosome
network. Mutations in VPS35 have been associated with alterations in the retromer complex with abnormal
trafﬁcking of the autophagy protein ATG9A leading to consequent autophagy impairment [20]. Additional
studies showed that loss of (as well as mutations in) VPS35 causes an additional abnormal trafﬁcking of the
lysosomal protein LAMP2a (lysosome-associated membrane protein 2), involved in CMA with consequent
impairment of α-synuclein degradation [21]. LAMP2a is another protein proposed in the PD-GWAS as a can-
didate risk factor for sporadic PD [17]; its levels were indeed found to be reduced in the substantia nigra and
amygdala of PD cases at a level shown to be sufﬁcient to impair CMA and increase the half-life of α-synuclein
[22]. WDR45 (WD repeat domain 45) is a protein mutated in neurodegeneration with brain iron accumulation
presenting with Parkinsonism [23]. Only very few studies are available; however, WDR45 has been proposed to
control autophagosome elongation [24]. ATP13A2 (ATPase 13A2) is a lysosomal type 5 P-type ATPase
mutated in the Kufor-Rakeb syndrome, a juvenile form of Parkinsonism presenting with dementia [25].
Alterations in ATP13A2 have been associated with lysosomal impairment, α-synuclein accumulation and a
decrease in cathepsin D activity [26]. Recently, it has been proposed that ATP13A2 may be capable of regulat-
ing SYT11 (synaptotagmin 11), another protein identiﬁed in PD-GWAS as a possible PD risk factor [18]. The
ATP13A2/SYT11 interaction may control lysosomal functionality, autophagy pathways and α-synuclein clear-
ance [27]. GBA (β-glucocerebrosidase) is an enzyme known for its association with Gaucher’s disease, a lyso-
somal storage disorder caused by homozygous mutations reducing the hydrolytic activity of GBA with
consequent built-up of undigested, highly toxic glucocerebroside within the lysosomes. Heterozygous mutations
in GBA cause a 20-fold increase in the risk of PD [28]. Inhibition of autophagy by inactivation of protein phos-
phatase 2A (PPP2A) [29] as well as engulfment of the endoplasmic reticulum (ER) with misfolded GBA
protein and consequent induction of ER stress [28] were postulated as a causal link between GBA mutations
and PD. Recently, GBA mutations (and enzyme deﬁciency) were associated with a peculiar, ﬁnal stage of
macroautophagy where lysosomes are recycled following the engulfment and digestion of the autophagosomes
[30]. Mutations in PINK1, parkin and FBXO7 (F-box only protein 7) lead to early-onset PD; the relevance of
these proteins in mitochondria quality control and mitophagy is well established [31]. SYNJ1 (synaptojanin 1)
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Figure 1. PD genes and autophagy-endolysosomal pathway(s).
Parkinson’s disease genes and their possible involvement in autophagy and endolysosomal pathway.
Figure 2. LRRK2 and autophagy-endolysosomal pathway(s).
LRRK2 and its possible involvement in autophagy and endolysosomal pathway (red boxes = increase, blue boxes = decrease in,
autophagy).
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is mutated in rare forms of PD [32]. Although not well studied to date, loss of SYNJ1 causes abnormal endoly-
sosomal trafﬁcking with accumulation of late endosomes and autophagosomes in cone photoreceptors of zebra-
ﬁsh with concomitant defects in autophagosome maturation [33]. Finally, a mutation in SMPD1
(sphingomyelin phosphodiesterase-1), a protein known for its association with Niemann-Pick lysosomal
storage disease, was recognized as strong risk factor for PD [34]. SMPD1 is a type of sphingomyelin phospho-
diesterase relevant for lysosomal homeostasis [35] and, potentially, autophagy [36].
The alluring scenario of a common pathogenic mechanism connecting all the genes related with PD was
further emphasized by the fact that autophagy-deﬁcient mouse models (following Atg7 knockdown) are
affected by presynaptic accumulation of α-synuclein, thus recapitulating one of the hallmarks of PD pathogen-
esis [37].
All this evidence, paired with the fact that macroautophagy constitutes a reasonable therapeutic target with
different drugs already approved, has led autophagy and the endolysosomal pathway, among other LRRK2
functions, to gain momentum, becoming the center of attention of many laboratories worldwide.
LRRK2 and the autophagy–endolysosomal pathway
The ﬁrst reports suggesting a role for LRRK2 in autophagy showed, in cellular models, that overexpression of
G2019S-LRRK2 in SHSY5Y cells was sufﬁcient to induce neurite shortening with a mechanism dependent on
macroautophagy [38], whereas LRRK2 silencing triggered an increase in the basal macroautophagy ﬂux [39].
These ﬁrst two works, published between 2008 and 2009, set the stage for many studies that investigated the
intriguing, though still incomplete and sometimes controversial, association of LRRK2 with the autophagy–
endolysosomal pathway (Figure 2).
LRRK2 has been studied in different model systems through overexpression (both wild-type and mutant
sequences), knockdown/knockout, chemical inhibition of kinase activity (while increase in kinase activity can
normally be achieved by expression of the G2019S-LRRK2 sequence), and in patient-derived cell cultures. As
detailed below, the investigation of LRRK2 modulation over macroautophagy has produced a complex and con-
troversial set of results (Table 1) showing (i) both a positive and a negative regulation of LRRK2 over macroau-
tophagy; (ii) a role for LRRK2 in both the initiation and the ﬁnal phases of autophagy and (iii) similar
Table 1 Open challenges for the study of LRRK2 in the context of autophagy-endolysosomal pathway(s)
Discordant reports regarding the role of LRRK2 in
macroautophagy
Positive and negative regulation of LRRK2 over macroautophagy
LRRK2 modulation of the initiation and termination phases of
macroautophagy
Similar outcomes following both inhibition and increase of
LRRK2 kinase activity
Technical challenges when integrating reports
concerning the role of LRRK2 in macroautophagy
Wide variety of model systems (e.g. different cell lines, human vs.
animal cells and different types of primary cultures)
Experiments performed at different LRRK2 expression levels (i.e.
overexpression vs. endogenous level)
Outcomes achieved by studying mutant LRRK2 are difficult to
recapitulate with results obtained with the wild-type sequence
Results obtained with mutant LRRK2 are difficult to summarize;
there are too many different mutations (G2019S appears to be the
most frequently studied), results are inconsistent showing
G2019S-LRRK2 to both potentiate and repress autophagy
depending on the model system/experimental procedure.
Chemical inhibition of LRRK2 kinase activity is difficult to
compare with knockdown/knockout strategies where the entire
LRRK2 protein is removed (comprising the kinase, GTPase and
protein interaction domains)
Unavailability of drugs and techniques to dissect LRRK2 kinase
vs. GTPase activities
A wide variety of strategies to stimulate/repress macroautophagy
coupled with different model systems may result in different
macroautophagy pathways and/or control feedback loops to be
activated
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outcomes following LRRK2 kinase activity inhibition (achieved by chemical inhibition and/or LRRK2 knock-
down/knockout) or increase (achieved by overexpression of G2019S-LRRK2).
As ﬁrst, overexpression of LRRK2 suggested a possible involvement in a dual control over macroautophagy
and lysosomal functionality by activating macroautophagy through a calcium signaling cascade controlled by
the calcium-dependent protein kinase kinase-β (CaMKK-β)/adenosine monophosphate (AMP)-activated
protein kinase (AMPK) pathway, and by reducing degradation through a concomitant increase in lysosomal
pH [40]. Along the same route, expression of mutant LRRK2 (R1441C, Y1699C and G2019S-LRRK2) in astro-
cytes resulted in formation of enlarged, but nonfunctional, lysosomes, with altered pH and increased expression
of ATP13A2 (in the case of G2019S-LRRK2) [41]. As these defects were rescued by chemical inhibition of
LRRK2, the increase in kinase activity following LRRK2 mutation may be responsible for the observed lysosomal
alteration. Chemical inhibition of LRRK2 kinase activity conﬁrmed a role for LRRK2 in the modulation of the
macroautophagy ﬂux, with apparently discordant results suggesting (i) a positive, mTOR-independent–
Beclin-1-dependent [42,43] and (ii) a negative [44] regulation of macroautophagy. Knockdown of LRRK2 (i.e.
silencing of its kinase activity) in immune cells resulted in impairment of macroautophagy and reduction of its
degradative capacity [45]. However, a similar outcome was obtained in the opposite scenario through overexpres-
sion of G2019S-LRRK2 (i.e. increased LRRK2 kinase activity) with disruption of aggregosome formation and
impairment in clearance when macroautophagy was assessed concomitantly with proteasome inhibition [46].
Other apparently conﬂicting results were obtained studying PD patient-derived cells carrying LRRK2 muta-
tions. Studies in mutant ﬁbroblasts suggested both increased based level of macroautophagy through activation
of the MEK/ERK pathway (only for G2019S-LRRK2) [47] and reduced response to induction of macroauto-
phagy following nutrient starvation and mTOR inactivation (for R1441G, Y1699C and G2019S-LRRK2) [48].
Neurons derived from PD ﬁbroblasts carrying G2019S-LRRK2 revealed alterations in macroautophagy,
however, at the level of autophagosome degradation [49].
LRRK2 animal models did not help in clarifying this complicated landscape. A ﬁrst LRRK2 knockout mouse
model showed a biphasic, age-dependent alteration in macroautophagy in the kidneys [50], whereas transgenic
mice expressing G2019S-LRRK2 showed age-dependent degeneration of nigrostriatal pathway and dopamin-
ergic neurons with autophagy and mitochondrial abnormalities [51]. Alongside macroautophagy, CMA has
been analyzed as this process was hypothesized to be important for LRRK2 turnover. CMA was found to be
impaired by mutant forms of LRRK2 mirroring a mechanism already suggested in the case of mutant
α-synuclein [52].
Although the relevance of LRRK2 in the control of autophagy is well documented and accepted by the scien-
tiﬁc community, it is clear that we are still missing many mechanistic details while many studies report contro-
versial results in regard to the actual molecular mechanism through which this control is exerted. There may
be multiple technical explanations for these inconsistencies (Table 1).
However, in the light of these sometimes confusing data, it may be worth considering again the dynamic
ability of LRRK2 to form complexes as it has been previously discussed. In fact, the data-hub hypothesis may
not only be relevant to the general array of LRRK2 functions; it may as well describe the role of LRRK2 in the
context of autophagy. Different cell types and different triggering circumstances may cause LRRK2 to interact
with different partners within the autophagy machinery enabling LRRK2 to control autophagy in slightly differ-
ent ways. In fact, speciﬁc roles for LRRK2 in the control of macroautophagy have been described when LRRK2
was part of speciﬁc protein complexes. Particularly, the LRRK2-mediated control of mitochondria homeostasis
through macroautophagy was described following interaction with the B-cell lymphoma 2 (Bcl-2) protein [53],
and this observation was further corroborated by the ﬁnding that Bcl-xL prevented macroautophagy alterations
induced by chemical inhibition of LRRK2 kinase activity [54]. LRRK2 promotion of Golgi-derived vesicle clear-
ance by macroautophagy was described only when LRRK2 was in complex with Bcl-2-associated athanogene
domain cochaperone 5 (BAG5), GAK and RAB7L1 [18]. Speciﬁcally at the presynaptic terminal, LRRK2 was
shown to be capable of regulating macroautophagy by phosphorylating EndophilinA, which in turn is capable
of modulating the membrane curvature, thus controlling the recruitment of the autophagy machinery to the
nascent autophagosome [55].
Conclusion
LRRK2 has been associated with many different functions among which is autophagy. Autophagy has a clear
role and impact in LRRK2-associated disorders. Since other PD genes have independently been linked to the
autophagy–endolysosomal pathway, this might represent a common mechanism to PD neurodegeneration.
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However, even if the study of LRRK2 in the context of autophagy has been extensive, the complete picture is
still unclear due to controversial results that are very difﬁcult to recapitulate in an exhaustive, unifying hypoth-
esis. I here suggest that, in addition to technical issues, one reason for this plethora of apparently discordant
ﬁndings can be the speciﬁc complex forming behavior of LRRK2. This suggests that, in different experimental
systems and cellular models, speciﬁc LRRK2 complexes may be formed and not necessarily be involved in the
same control/function. Therefore, to understand the dynamic lynchpin activity of LRRK2, we should start shift-
ing the focus of our attention from close-up (i.e. LRRK2 in isolation) to the wider perspective of the experi-
mental context.
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